The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: A single-institution experience

Irit Ben Aharon, Ofer Purim, Yulia Kundel, Ronen Brenner, Noa Gordon, Aaron Sulkes, Baruch Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

The addition of docetaxel to cisplatin and 5-fluorouracil was shown to confer a survival benefit in patients with advanced gastric cancer (one; AGC), although with increased toxicity. We hereby report our experience with the use of docetaxel, cisplatin, and 5-fluorouracil (DCF). Data on all consecutive patients who received first-line treatment with DCF at our institute were analyzed retrospectively. Twenty-three patients were included. The median age was 63 years. Patients received an average of 10 cycles (range, 1-24). All experienced grade ≥3 toxicity, requiring hospitalization in 35%. There was one toxic death. The median progression-free and overall survival rates were 10.0 and 12.8 months, respectively; the 2-year and 3-year survival rates were 22 and 17%, respectively. The DCF regimen is indeed associated with substantial toxicity, although manageable. Nevertheless, the observed benefit was remarkable compared with any previous report on chemotherapy in AGC, and should therefore represent a valid treatment option in AGC and a platform for future combinations.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalAnti-Cancer Drugs
Volume23
Issue number3
DOIs
StatePublished - Mar 2012

Keywords

  • Docetaxel
  • Gastric cancer
  • Locally advanced
  • Metastatic

Fingerprint

Dive into the research topics of 'The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: A single-institution experience'. Together they form a unique fingerprint.

Cite this